Vivani Medical VANI Biopharm Division — Operating Lease Expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Vivani Medical in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseExpense.
The official record: Vivani Medical’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vivani Medical's biopharm division — operating lease expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vivani Medical's biopharm division — operating lease expense?
- Vivani Medical (VANI) reported biopharm division — operating lease expense of $1.13M in Q1 2026.
- How has Vivani Medical's biopharm division — operating lease expense changed year-over-year?
- Vivani Medical's biopharm division — operating lease expense increased by 6.1% year-over-year, from $1.06M to $1.13M.
- What is the long-term trend for Vivani Medical's biopharm division — operating lease expense?
- Over 2 years (2023 to 2025), Vivani Medical's biopharm division — operating lease expense has grown at a 2.8% compound annual growth rate (CAGR), from $3.99M to $4.21M.
- What does biopharm division — operating lease expense mean?
- Includes the costs associated with leasing facilities, laboratories, or equipment essential for the biopharmaceutical segment's operations. This metric reflects the fixed overhead burden required to maintain the physical infrastructure for research activities. It is an important component of the segment's recurring operational cost structure.